Approximately 99% of CML patients in this study are BCR-ABL positive, with the majority being major b3a2 breakpoint (74.32%) followed by major b2a2 breakpoint (22.34%). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.